RISS 검색 - 국내학술지논문 상세보기

다국어 초록 (Multilingual Abstract)

Purpose: The Korean Renal Cancer Study Group (KRoCS) provides consensus recommendations on the role of cytoreductive nephrectomy (CRN) in patients with metastatic renal cell carcinoma (mRCC).Materials and Methods: A group of mRCC experts from the Korean Urological Oncology Society convened at the 2021 KRoCS meeting on CRN for mRCC.Results: The consensus document was developed to address 4 questions related that were judged to be the most relevant to patient care: (1) Is there a role for CRN in patients planning targeted therapy? (2) Is there a role for CRN in patients planning immuno-oncology agents? (3) When is the optimal time of CRN in patients planning systemic treatment? (4) What is the ideal patient selection for CRN? The panelists have come up with following consensus. For mRCC patients, CRN should be considered only in those with IMDC (International Metastatic Renal Cell Carcinoma Database Consortium) favorable and intermediate risk disease, regardless of the systemic treatment plans. Timing of CRN should consider the risk group as well as the number of risk factors, but is generally recommended for after assessing the degree of response to initial systemic treatment. Patients with good performance status, limited metastatic burden on top of resectable primary tumor are candidates recommended for CRN with or without metastasectomy with priority.Conclusions: In conclusion, there is still a role for CRN in the multimodality treatment of mRCC. Careful patient selection is of paramount importance. As the treatment landscape of mRCC continues to change, the role of CRN in the current immuno-oncology era will require more exploration.

번역하기

참고문헌 (Reference)

1 Manley BJ, "Validation of preoperative variables and stratification of patients to help predict benefit of cytoreductive nephrectomy in the targeted therapy ERA" 43 : 432-439, 2017

2 Conti SL, "Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era" 134 : 2245-2252, 2014

3 Bex A, "Updated European Association of Urology Guidelines for cytoreductive nephrectomy in patients with synchronous metastatic clear-cell renal cell carcinoma" 74 : 805-809, 2018

4 Powles T, "The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer" 60 : 448-454, 2011

5 Choueiri TK, "The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy" 185 : 60-66, 2011

6 Bedke J, "The 2021 Updated European Association of Urology Guidelines on renal cell carcinoma : immune checkpoint inhibitor-based combination therapies for treatment-naive metastatic clear-cell renal cell carcinoma are standard of care" 80 : 393-397, 2021

7 Hudes G, "Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma" 356 : 2271-2281, 2007

8 Bhindi B, "Systematic review of the role of cytoreductive nephrectomy in the targeted therapy era and beyond : an individualized approach to metastatic renal cell carcinoma" 75 : 111-128, 2019

9 De Groot S, "Survival in patients with primary metastatic renal cell carcinoma treated with sunitinib with or without previous cytoreductive nephrectomy : results from a populationbased registry" 95 : 121-127, 2016

10 Marchioni M, "Survival after cytoreductive nephrectomy in metastatic non-clear cell renal cell carcinoma patients : a population-based study" 5 : 488-496, 2019